The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the weight loss community. This innovative dual GIP and GLP-1 target medication seems to offer notable improvements in weight reduction compared to previous therapies. Preliminary patient data have demonstrated significant reductions in weight ,